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Abstract
Introduction: The goal was to identify which neurochemicals differ in professional athletes with repetitive brain
trauma (RBT) when compared to healthy controls using a relatively new technology, in vivo Localized COrrelated
SpectroscopY (L-COSY).
Methods: To achieve this, L-COSY was used to examine five former professional male athletes with 11 to 28 years
of exposure to contact sports. Each athlete who had had multiple symptomatic concussions and repetitive sub
concussive trauma during their career was assessed by an experienced neuropsychologist. All athletes had clinical
symptoms including headaches, memory loss, confusion, impaired judgment, impulse control problems, aggression,
and depression. Five healthy men, age and weight matched to the athlete cohort and with no history of brain
trauma, were recruited as controls. Data were collected from the posterior cingulate gyrus using a 3 T clinical
magnetic resonance scanner equipped with a 32 channel head coil.
Results: The variation of the method was calculated by repeated examination of a healthy control and phantom
and found to be 10% and 5%, respectively, or less. The L-COSY measured large and statistically significant differences
(P ≤0.05), between healthy controls and those athletes with RBT. Men with RBT showed higher levels of glutamine/
glutamate (31%), choline (65%), fucosylated molecules (60%) and phenylalanine (46%). The results were evaluated
and the sample size of five found to achieve a significance level P = 0.05 and a power of 90%. Differences in N-acetyl
aspartate and myo-inositol between RBT and controls were small and were not statistically significance.
Conclusions: A study of a small cohort of professional athletes, with a history of RBT and symptoms of chronic
traumatic encephalopathy when compared with healthy controls using 2D L-COSY, showed elevations in brain
glutamate/glutamine and choline as recorded previously for early traumatic brain injury. For the first time increases in
phenylalanine and fucose are recorded in the brains of athletes with RBT. Larger studies utilizing the L-COSY method
may offer an in-life method of diagnosis and personalized approach for monitoring the acute effects of mild traumatic
brain injury and the chronic effects of RBT.
Introduction
There is increasing recognition of long-term neurological
difficulties from head injuries, especially from repetitive
concussive and sub-concussive brain trauma. Chronic
traumatic encephalopathy (CTE) is a progressive neurode-
generative disease, found post mortem, in individuals with
histories of repetitive brain trauma (RBT), such as contact
sport athletes and combat military personnel [1]. Early
symptoms of RBT include impaired memory and execu-
tive functioning. Mood disturbance, including depression,
apathy, suicidal tendencies and behavior change, follow as
do impulsivity and aggression [1]. Later in the disease
course, dementia can develop as well as motor disturb-
ance in some people [2]. Autopsy studies have revealed a
distinct pattern of neuropathological changes known as
CTE which includes: tau-immunoreactive proteins in the
cerebral cortex; neurofibrillary and glial tangles; generalized
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atrophy; enlarged ventricles; degeneration of white matter
fiber bundles; cavum septum pellucidum; and a relative
absence of beta-amyloid (Aβ) deposits [3,4].
The neuropathological diagnosis of CTE is well docu-
mented but there is a need for an in vivo diagnosis to
provide an in life and personalized approach to manage
this disease. An in life test will also facilitate research into
the risk factors, epidemiology, prevention and treatment.
Magnetic resonance spectroscopy (MRS) can be used to
noninvasively record neurochemical changes as a result of
RBT. One-dimensional MRS allows neurochemicals, mo-
bile on the MR timescale, to be monitored noninvasively
in a clinical MR scanner [5]. However, many of these neu-
rochemicals overlap in the one-dimensional MR spec-
trum making it difficult to determine the precise level of
change to each chemical population. A single chemical
species can be measured at one time using MR spectral
editing techniques [6-8] but these do not allow com-
parison of how the neurochemicals alter in relation to
one another [9,10].
The introduction of Localized (L) COrrelated Spectros-
copY (L-COSY) overcame this issue [11,12]. L-COSY
utilizes a simple three-pulse sequence:
90ϕ1−180ϕ2−t1−90ϕ3−Acqϕ4 ϕ is phaseð Þ
whereby each row in the final spectrum is acquired in
succession and t1 time delay is incremented by a set
value, thereby providing a two-dimensional spectrum. In
an L-COSY spectrum, a ‘cross peak’ off the diagonal
indicates scalar coupling between the two protons it
connects on the diagonal, thus providing chemical speci-
ficity not available to conventional one-dimensional
MRS. Using data collected in a whole body commercially
available scanner at 3 T, there are many more molecules
now open for inspection in the brain using the L-COSY
method with higher certainty. This L-COSY method has
been applied successfully to other organs including
muscle and bone marrow [13] and brain [11]. The ad-
vantage of L-COSY is that it allows for unambiguous
identification and measurement of metabolites, lipids
and macromolecules, compared to the one-dimensional
MR spectra [14]. For the brain, the L-COSY allows over
35 different resonances to be inspected, each of which
can be related to function, disease or injury [11].
The L-COSY protocol, using the 32 channel head coil,
was previously reported to be effective for studying the
human brain with a signal to noise ratio sufficient to
monitor the neurochemicals from healthy brain and gli-
oma [11]. The spectral quality allowed similar chemical
information, recorded from cultured cells at 8.4 T, to be
seen in vivo from the brain of patients with glioblastoma
in a 3 T clinical scanner. In the glioma study, the
changes to neurochemistry were large. Much smaller
changes were anticipated from subjects with RBT. Here, we
report the results of a pilot study, using the L-COSY
method, on chronic sports-induced repetitive head injury
in elite athletes compared with healthy age-matched con-
trols with no history of head injury. Although the cohort is
small, we report large differences in neurochemistry, with




Data were acquired on a 70 cm wide bore Siemens Verio
(Siemens AG, Erlangen, Germany) using the operating soft-
ware VB17 using the 32 channel head coil (Siemens AG).
MRI and MRS protocol
Prior to the spectroscopy data collection, routine brain
magnetic resonance imaging (MRI) was performed with
axial 3D-MPRAGE and reconstructed in the sagittal and
coronal planes with 2 mm slice resolution for accurate
localization of the voxel. The posterior cingulate gyrus
(PCG), predominantly comprising gray matter, was chosen
for examination as it had been reported to be sensitive to
traumatic brain injury [15,16]. Furthermore, post mortem
CTE studies show deposition of tau protein in the cortical
gray matter areas including the cingulate [3].
The L-COSY protocol was undertaken as described in
Ramadan et al. [11] with a 32 channel head coil, using
64 increments with 8 averages, and a repetition time
(TR) of 1.5 seconds resulting in an acquisition time of
12.8 minutes. The data were acquired from a voxel in
the PCG (size 3 × 3 × 3 cm3), acquired vector size 1,024
points; acquisition time 512 ms; spectral width in F2
2,000 Hz and spectral width in F1 1,250 Hz (0.8 ms
increment size).
Localized shimming was undertaken by adjustment of
zero- and first-order shim gradients using the automatic B0
field mapping technique supplied by the vendor (Siemens
AG) followed by manual adjustment of zero-order shim
gradients to achieve a resulting peak width of water at
half-maximum that was 14 Hz or less. Following fre-
quency adjustment, water-selective suppression was
achieved using the WET-technique [17] programmed into
the pulse sequence.
Subjects
The study was approved by the local institutional review
boards (Partners Human Research Committee and Boston
University Medical Campus Institutional Review Board)
and was compliant with the Health Insurance Portability
and Accountability Act. All subjects provided informed
consent and consent for publication.
Five retired professional male athletes participated in
the study (43.6 ± 10.8 years) (Table 1). They had 11 to
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28 years (17.4 ± 7.2 years) of exposure to repetitive brain
trauma in contact sports, including American football
(n = 3), professional wrestling (n = 1) and baseball (n = 1).
Each athlete had experienced multiple symptomatic
concussions (including several concussions with loss of
consciousness) as well as repetitive sub-concussive trauma
during his career. The subjects were all examined at the
chronic stage of injury 3 to 25 (13.8 ± 10.1) years since the
end of their careers and had no recently reported head in-
juries. Subjects were each evaluated by an experienced
neuropsychologist (RAS) within a few days of MR examin-
ation via a personal interview; a semi quantitative neuro-
psychological test score was assigned to each (see Table 1).
All five former athletes had reported clinical symptoms
associated with either prolonged post-concussive syn-
drome or early CTE, including headaches, memory loss,
confusion, impaired judgment, impulse control problems,
aggression and depression [2]. Five healthy men, who were
not professional athletes, were recruited as control sub-
jects. They were age and weight matched to the athletes
(45.2 ± 12.6 years; no significant difference from subjects),
with no history of brain trauma.
To determine the variation of each cross peak using
this L-COSY sequence, data were accrued four times in
succession from phantom solutions of the major metabo-
lites (N-acetyl aspartate, creatine, choline and myo-inositol)
at physiological concentrations and pH as well as five times
in succession in a volunteer (man, age 42). The coefficient
of variation of each cross peak was calculated.
Data processing
Raw L-COSY data were transferred to MATLAB [18] for
signal combination from multiple elements followed by
row concatenation into a two-dimensional matrix. Com-
mercial two-dimensional spectral processing software
(Felix-2007, Accelrys, San Diego, CA, USA) was used for
observer-independent spectral processing and analysis.
The processing parameters used were: F2 domain (skewed
sine-squared window, 2,048 points, magnitude mode), F1
domain (sine-squared window, linear prediction to 96
points, zero-filling to 512 points, magnitude mode). The
effect of altering time domains and window functions in
two-dimensional COSY has been documented elsewhere
[19]. Residual water was removed by using a Felix built-in
Gaussian shaped convolution-based method. The total
creatine methyl diagonal resonance at 3.02 ppm was used
as an internal chemical shift reference in F1 and F2. All
‘cross’ or off-diagonal peaks are denoted with F2 – F1 in
ppm units. When preparing the spectra for figures, each
spectrum was calibrated by setting the lysine cross peak
(at 3.00– 1.67 ppm) and specifying a constant ‘number of
contour levels’ (set to 28), as well as a constant ‘level
multiplier’ (defined as the difference between values of
consecutive contour, set to 1.05). The volumes of cross
peaks or diagonal resonances were evaluated using Felix
software described above, and care was taken to ensure
that the interrogated volume was the same in all L-COSY
spectra. To further avoid operator bias, this was done by
creating a fixed template to analyze the L-COSY data. All
identifiable peaks according to Govindaraju [20], Lean
[21] or Ramadan [11] were reported and peaks were
measured and normalized to the creatine diagonal peak
volume at 3.02 ppm for comparable results across all
scans. The post processing that was ultimately chosen for
the study was the same as for the glioma study [11].
Statistical analysis
Wilcoxon ranked sum tests were performed to deter-
mine statistical significance. Bonferroni correction was
not used due to the small sample size, the large number
of independent variables and the pilot nature of this
study. A significance level of 0.05 was utilized to com-
pare data from the RBT cohort and healthy controls.
Altman's Nomogram [22], determined by the size of the
differences was employed to determine the minimum
sample size for P ≤0.05 at a level of 90% significance for
future studies.
Results
Variation of the L-COSY method
The in vivo coefficients of variation are summarized in
Table 2 where the internal reference creatine had a vari-
ation of 1% while the other metabolites were 10% or less.
In the phantom solutions, a variation of 5% or less was
obtained.
The mean cross peak area of lysine (Lys, at 3.00–
1.67 ppm) referenced to creatine was found to be the
same in both RBT subjects and controls. Therefore, Lys
was used to set the same contour levels across all data
sets for presentation.










A 30 to 35 Football/
Wrestling
3 11 +
B 30 to 35 Football 7 28 ++
C 30 to 35 Baseballa 7 11 ++
D 40 to 55 Football 9 21 ++
E 40 to 55 Football 7 16 +++
aIn addition to baseball-related concussions, subject also had several
concussions from non-sports-related activities.
+mild cognitive and neuropsychiatric symptoms; ++moderate cognitive and
neuropsychiatric symptoms; +++significant cognitive and neuropsychiatric
symptoms. RBT, repetitive brain trauma.
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Healthy versus repetitive brain trauma
Importantly, none of the athletes recorded structural
MRI abnormalities using conventional imaging metrics.
A typical L-COSY spectrum from a healthy male with no
history of brain trauma is shown in Figure 1A. This is
compared to L-COSY data recorded from a professional
male athlete of similar age and weight, with history of
RBT, and with cognitive symptoms in Figure 1B. These
representative spectra demonstrate well-resolved cross
and diagonal peaks including amino acids: alanine, aspar-
tate, isoleucine, leucine, lysine, taurine, threonine (Thr),
phenylalanine (Phe); membrane phospholipids: glycero-
phosphorylcholine, phosphocholine, phosphoethanolamine;
neurotransmitters: γ-amino-butyric acid (GABA), glutam-
ate/glutamine (Glx); major metabolites: N-acetyl aspartate
(NAA), choline (Cho), creatine (Cr), myo-inositol (mI),
glutathione (GSH), taurine, lactate, multiple lipid reso-
nances, and macromolecules.
Large and significant differences in neurochemical levels
were recorded when comparing age-matched RBT subjects
to controls using non-parametric tests (P ≤0.05). Summa-
rized in Table 3 and Figure 2 (scatterplot) are those cross
peaks which are significantly different. Additional metabo-
lites of interest such as NAA and mI (both have been
shown to change in other traumatic brain injury (TBI)
studies [23,24]) where changes were small or not statisti-
cally significant in this pilot series are also shown (Table 4).
The RBT cohort recorded an increase of 31%, 32%
and 35% in the glutamine/glutamate cross peaks (2.09–
3.75 ppm, 2.07–3.73 ppm and 2.14–3.74 ppm, respect-
ively) (Table 3) when compared to controls. Figure 2
clearly demonstrates that for most of the Glx resonances
there is no overlap between the RBT and control cohorts. It
remains contentious as to whether glutamate and glutam-
ine resonances are separable; thus, it cannot yet be ascer-
tained if the increase is in glutamine or glutamate or both.
The methylene group of choline at 4.05–4.05 ppm was
65% higher in the RBT cohort. The scatterplot (Figure 2)
shows that there is no overlap between the cross peak
values measured in RBT subjects and controls. It is
Table 2 Reproducibility of the L-COSY method: single




Cr N(CH3) 3.02–3.02 1





tCho (CH3)3-N + −CH2-CH2-OH 4.05–4.05 2
Fucose region
and Thr
-CH(OH)-CH3 CH3-CH (F2: 4.0–4.5,
F1: 1.1–1.7)
10
Phe -CH-(aromatic)- 7.33–7.33 7
NAA -CH3 2.00–2.00 2
Cho (CH3)3-N + −CH2-CH2-OH 3.51–4.05 3
(CH3)3-N + −CH2-CH2-OH 3.20–3.20 5
mI -CH(OH)-CH(OH) 3.63–3.29 5
3.55–3.55 3
Abbreviations: Cho, choline; Cr, creatine; Glx 1-7, crosspeaks of glutamate +
glutamine; L-COSY, localized correlated spectroscopy; mI, myo-inositol; NAA,
N-acetyl aspartate; Phe, phenylalanine; ppm, parts per million; Thr, threonine. In
bold are the proton groups that give rise to the crosspeak chemical shifts
indicated in the third column.
Figure 1 L-COSY spectra. A) Age-matched healthy control; B) Athlete with history of RBT. Spectroscopy was performed at 3 T using a 32 channel
head coil and voxel size of 3 × 3 × 3 cm3 in the PCG; increment size 0.8 ms; 64 increments with 8 averages resulting in an acquisition time of 12.8
minutes; acquired vector 1,024 points; acquisition time 512 ms; spectral width in F2 2,000 Hz and spectral width in F1 1,250 Hz. Assigned neurochemicals
are according to Ramadan et al. [11] and Lean [21]. For presentation, the spectra were calibrated to the lysine cross peak at 3.00–1.67 ppm. Abbreviations:
N-acetylaspartate (NAA), choline (Cho); creatine (Cr); glutamate (Glu) and glutamine together (Glx); aspartate (Asp); myoinsitol (mI); lysine (Lys); threonine
(Thr), gamma-aminobutyric acid (GABA). L-COSY, localized correlated spectroscopy; PCG, posterior cingulate gyrus; RBT, repetitive brain trauma.
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interesting to note that while the mean peak volumes of the
choline resonances at 3.20–3.20 ppm and 3.51–4.05 ppm
were greater, they were not statistically significant.
L-COSY also uniquely identifies additional resonances
that cannot be characterized by one-dimensional MRS
methods. For example, the cross peaks in the F2: 4.0–
4.5, F1: 1.1–1.7 region, show a higher cross peak volume
in molecules assigned to covalently linked terminal fu-
cose molecules and threonine [21] of 60% in the RBT
group [21]. The spectral region (F2: 4.0–4.5, F1: 1.1–1.7)
contains threonine, fucose and, sometimes, lactate cross
peaks. Originally assigned in the two-dimensional COSY
from cultured cells [21,25] and more recently in vivo in
the brain [11], these fucose cross peaks are also seen in
the brain spectra reported by Velan et al. [14], but
assigned to Thr/lactate alone. The assignment of bound
fucose in the two-dimensional MR spectra was previously
made using in vitro models by treating the cultured cells
Table 3 Statistically significant differences between healthy and RBT subjects







Glx-1 -CH2- CH(NH3+) 2.09–3.75 0.112 ± 0.009 0.147 ± 0.017 31 ± 18 3.11
Glx-3 2.07–3.73 0.022 ± 0.002 0.029 ± 0.004 32 ± 21 2.70
Glx-4 2.14–3.74 0.031 ± 0.002 0.042 ± 0.007 35 ± 24 2.88
Glx-6 2.45–2.01 0.018 ± 0.001 0.041 ± 0.011 77 ± 6 6.28
tCho (CH3)3-N + −CH2-CH2-OH 4.05–4.05 0.250 ± 0.071 0.413 ± 0.051 65 ± 36 3.54
Fucose region and Thr -CH(OH)-CH3 CH3-CH (F2: 4.0–4.5, F1: 1.1–1.7) 0.022 ± 0.007 0.036 + 0.011 64 ± 61 2.64
Phe -CH-(aromatic)- 7.33–7.33 0.024 ± 0.005 0.035 ± 0.008 46 ± 40 2.08
Cross peak volumes were calculated relative to creatine. % Diff is the difference of the control and RBT means divided by the control mean ± the
standard deviation. In bold are the proton groups that give rise to the crosspeak chemical shifts indicated in the third column.
Abbreviations: Glx, crosspeaks of glutamate + glutamine; Phe, phenylalanine; RBT, repetitive brain trauma; tCho, total choline; Thr, threonine.
Figure 2 Scatterplot of significantly different (P ≤0.05) metabolites. The normalized cross peak areas, as measured in the posterior cingulate
gyrus using L-COSY, of the different resonances of glutamate-glutamine (Glx-1,3,4,6), choline (Cho), fucosylated glycans and threonine and phenylalanine
(Phe) are shown for RBT subjects in red boxes and age-matched controls in blue circles. For clarity, choline is plotted on a secondary y-axis (right) due to
the difference in the values which is highlighted in blue. L-COSY, localized correlated spectroscopy; RBT, repetitive brain trauma.
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with fucosyl transferase and observing the bound cross
peaks disappear and free α fucose at 1.22–4.21 ppm and
free β fucose at 1.26–3.81 ppm appear [25]. It is the unique
conformation of each of these terminal fucosylated species
on the oligosaccharide chain on the cell membrane that
generates the different chemical shifts for each fucose.
Replicating this in a phantom is, thus, not possible [26].
An expansion of the aromatic region (F2: 6.00–9.00 ppm;
F1: 6.00–9.00 ppm) where resonances [20] from phenyl-
alanine (Phe; 7.33–7.33 ppm); imidazole from histamine
and homocarnosine (Imi; 7.07–7.07 ppm); and high-
frequency peak from NAA amine group and imidazole
from histamine and histidine (HF; 7.82–7.82 ppm) on the
diagonal are shown in Figure 3 as expanded from Figure 1.
Phenylalanine was 46% higher in RBT subjects compared
with controls and statistically significant.
Based on the literature, two other molecules expected to
increase with RBT were NAA and myo-inositol (Table 4).
They were increased by 7% and 10%, respectively; how-
ever, these changes were relatively small and they did not
reach statistical significance [22]. This is of particular
interest given that these metabolites have been shown to
be significantly altered in other studies of head injury but
do not appear to be different in this limited cohort.
Discussion
Neurochemical changes with chronic repetitive brain trauma
This study demonstrates that the L-COSY method docu-
ments neurochemical differences in former professional
athletes with a history of RBT compared to healthy age-
matched controls with no history of head injury. Changes
in cerebral metabolites after severe TBI, in both children
and adults, have shown strong correlations with clinical
grade and patient outcome in previous studies [16,27,28].
The changes expected from previous one-dimensional
MRS of sports-related TBI’s [9,10,29] included changes in
NAA, choline and glutamine in acute and sub-acute stages
of injury. However, this is the first study to examine the
chronic changes in athletes with a history of RBT and the
first to apply two-dimensional L-COSY methodology. An
important outcome from this study is the ability to moni-
tor a larger range of molecules with greater accuracy. For
example, large increases in glutamine/glutamate, choline
and phenylalanine are evident and molecules such as the
Table 4 Additional metabolites of interest







NAA -CH3 2.00–2.00 1.215 ± 0.101 1.294 ± 0.070 7 ± 10 0.95
tCho (CH3)3-N + −CH2-CH2-OH 3.51-4.05 0.018 ± 0.002 0.020 ± 0.016 11 ± 81 0.23
(CH3)3-N + −CH2-CH2-OH 3.20-3.20 0.726 ± 0.009 0.774 ± 0.052 7 ± 7 1.63
mI -CH(OH)-CH(OH) 3.63–3.29 0.029 ± 0.013 0.032 ± 0.011 10 ± 61 0.26
3.55–3.55 0.342 ± 0.013 0.354 ± 0.029 4 ± 10 0.58
Data are presented as described in Table 3, that is, relative to creatine. In all cases, the differences between control and RBT were not statistically significant.
Abbreviations: mI, myo-inositol; NAA, N-acetyl aspartate; RBT, repetitive brain trauma; tCho, total choline. In bold are the proton groups that give rise to the
crosspeak chemical shifts indicated in the third column.
Figure 3 An expansion of the aromatic region (F2: 6.00–9.00 ppm; F1: 6.00–9.00 ppm). Resonances from phenylalanine (Phe; 7.33–7.33);
imidazole from histamine and homocarnosine (Imi; 7.07–7.07); and high-frequency peak from NAA amine group and imidazole from histamine
and histidine (HF; 7.82–7.82) are on the diagonal. The data are again expanded from Figure 1. On the left are the results from the healthy control
and on the right from the athletes with RBT, in which phenylalanine cross peaks are well visualized. There is a mean statistically significant greater
phenylalanine by 46% in the RBT group as a whole. NAA, N-acetyl aspartate; RBT, repetitive brain trauma.
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fucosylated glycans are now available for inspection in the
brain in vivo. While the changes observed in this cohort
are not necessarily representative of the heterogeneous
population of athletes with RBT, these preliminary results
may provide new insights into the biochemical pathways
being altered as a function of RBT.
The composite glutamate/glutamine was over 30%
higher in the athletes with RBT. Glutamate is a major
excitatory neurotransmitter and neuronal biomarker, the
increase in which is known to be predictive of poor
outcome in severe TBI [30]. Glutamine, the second
metabolite contributing to the region designated Glx, is
a predominantly glial metabolite and may, therefore,
provide information relevant to the gliosis or neuroin-
flammation identified in other studies of Alzheimer
disease (AD) [31] and hepatitis [32]. TBI alters the brain
homeostasis resulting in the activation of microglia via
proinflammatory cytokines [33] and in mouse models of
CTE, repetitive brain injury resulted in augmentation of
tau pathology as well as glial activation [34]. Recently,
resting and activated glial density was shown to be
increased in subjects with CTE when compared with
controls, and those with CTE and motor neuron disease
showed even greater glial density [35]. Another link to
CTE can be found in the clinical features of CTE. Recent
work has shown, through next-of-kin interviews of 36
athletes all with neuropathologically confirmed CTE, a
distinct initial clinical presentation at a younger age of
behavioral and mood disturbances and initial presentation
at an older age that involved cognitive impairment [36].
Several studies have shown that changes in glutamate
occur in depression and other mood disorders [37,38].
Choline was 65% higher in RBT subjects. Importantly,
there was no overlap between the choline values of each
group, thereby demonstrating a distinct difference be-
tween the RBT and control groups. Previous studies have
demonstrated that increased total choline which includes
several related membrane metabolites (phosphocholine,
glycerophosphocholine, phosphoethanolamine, glycero-
phosphoethanolamine, and so on) is reflective of brain
tissue damage or diffuse axonal injury in TBI [39]. It is
unclear at this time if the unambiguous choline mea-
sured by COSY is part of the same mechanism but the
large difference in this small cohort bears further study.
The cross peaks assigned to fucosylated glycans at (F1
0.90–1.70; F24.0–4.50) increased by 60% in subjects with
RBT. The levels of fucosylated epitopes, for example, sia-
lyl Lewis x, have been shown to increase during the early
events of inflammation [40-43]. Others have shown that
fucosylation of glycoproteins increases in inflammation
which may be related to the inflammation shown in
chronic brain injury by positron emission tomography
(PET) studies [44]. In the healthy brain fucose-α(1–2)-
galactose (Fucα(1–2)Gal] sugars have been implicated in
the molecular mechanisms that underlie neuronal devel-
opment, learning and memory [26]).
Phenylalanine, increased by 46% in the brains of the
RBT cohort, can be converted into tyrosine - another of
the DNA-encoded amino acids. Tyrosine, in turn, is con-
verted into 3,4-dihydroxyphenylalanine (Dopa), which is
further converted into dopamine, noradrenalin and
adrenaline [45]. This elevation may well be the result of
interference with a critical part of the noradrenergic and
adrenergic neurotransmitter pathways after RBT. Phenyl-
alanine in increased quantities also interferes with the
production of serotonin, an imbalance of which is thought
to influence mood in a way that leads to depression [46].
Finally, mI was not found to be significantly different
in RBT subjects. Previous studies have shown that brain
trauma is a risk factor for dementia [47,48] which has led
some to believe that the underlying cause for dementia
following TBI may be CTE and not AD in itself [49,50].
Although CTE is neuropathologically distinct from AD
[4], the same study also showed that 11% of the American
football players had co-morbid AD. Furthermore, the
differential diagnosis of these two diseases in life is difficult
if not possible based solely on clinical presentation. Just as
in AD, initial symptoms of CTE can include impaired epi-
sodic memory and in late stage CTE dementia can be cli-
nically mistaken for AD [2]. As a result, the relationship
between TBI and neurodegenerative disease, such as AD,
will remain unclear until a two-dimensional L-COSY study
is undertaken on AD and a larger RBT cohort.
Study limitations and future studies
A major limitation to this study is the small sample size.
The goal of this pilot investigation was to establish initial
data on the utility of L-COSY MRS in distinguishing
individuals with a history of RBT from healthy controls.
It is not possible to determine if the changes observed in
this small sample of former athletes with histories of
RBT are indicative of the progressive neurodegenerative
disease CTE or are a reflection of the residual, chronic
effects of the initial brain injuries. Furthermore, head
injury is heterogeneous and, thus, a larger sample may
have a greater variability that is not reflected in this
small cohort. Additional studies are planned to focus on
this and other important issues with the goal of utilizing
L-COSY MRS as a biomarker for CTE.
The capacity to measure changes in this larger number
of neurochemicals at one time, with high accuracy, and on
a personalized basis, is now possible using the L-COSY
technique. Such an approach could alter long term care of
the patients with RBT and other neurological diseases.
Much interest lies in clarification as to whether the data
presented here are the result of persistent, chronic post-
concussion syndrome and/or the neurodegenerative dis-
ease identified post mortem as CTE. This question will
Lin et al. Alzheimer's Research & Therapy  (2015) 7:13 Page 7 of 9
not be answered quickly as individuals need to be followed
over time. However, of more immediate use is the L-
COSY method to assist with a multi-modal biomarker
diagnostic approach to CTE, leading to the ability to
examine risk factors and prevalence of this neurodegen-
erative disease, as well as to understand better the pre-
vention and treatment of RBT.
Conclusions
This study demonstrates that two-dimensional L-COSY can
document neurochemical changes in former professional
athletes who have experienced RBT and symptoms includ-
ing headaches, memory loss, confusion, impaired judgment,
impulse control problems, aggression and depression. Large
and significant increases in the neurochemicals glutamate/
glutamine and choline are recorded as expected from earl-
ier studies but phenylalanine and fucosylated molecules
have not been recorded previously in RBT or mTBI. The
literature links these four neurochemicals to glutamatergic
neurotoxicity, diffuse axonal injury, neurotransmitter dys-
function and neuro inflammation. These results need to be
confirmed by future studies with a larger cohort that may
provide the basis for developing in life diagnosis of CTE.
For smaller differences recorded, the appropriate group
sizes were calculated to guide future study sizes.
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